Trump needs to prove he's serious about science; PTC's latest move is a jaw dropper
Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.
Two big steps back for the Trump administration
With Donald Trump in the White House, it’s always one step forward and two steps back for biopharma. So last week we had Scott Gottlieb’s nom for FDA commissioner (a big step forward) followed by this week’s news that Trump’s budget plans to slash NIH spending by close to $6 billion, while doubling industry’s fees to the FDA (you guessed it.)
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.